Core Insights - Next Health has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on personalized wellness and innovative aesthetic treatments [1] - The collaboration aims to conduct a structured assessment of Obagi's saypha MagIQ™ filler, leveraging Next Health's expertise in holistic protocols and patient-centric education [2] Company Overview - Obagi Medical is recognized for its advanced skincare solutions, with over 35 years of experience, and is the fastest-growing professional skincare brand in the U.S. as of 2024 [6][10] - Next Health, founded in 2016, specializes in health optimization and longevity, offering services like IV therapy and hormone optimization through a network of wellness centers [7] Program Details - The ALOHA Program evaluates clinical efficacy and patient experience, aiming to enhance satisfaction and loyalty through integrated Obagi protocols [3] - Standardized data will be collected across Next Health locations, with initial findings to be shared at leadership meetings and major industry conferences [3] Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Core Insights - Obagi Medical has partnered with Alpha Aesthetic Partners for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program, highlighting a commitment to innovation and education in aesthetic medicine [1][4] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, focusing on various skin concerns including hyperpigmentation and premature aging [6] - Alpha Aesthetics Partners, founded in 2023, aims to advance the medical aesthetics industry through best-in-class support and clinical training, with a growing presence across 31 locations in 12 states [7] Program Details - The ALOHA Program will involve a structured, multi-site evaluation of Obagi's saypha MagIQ™ across Alpha's network, aiming to generate real-world evidence of the product's integration into clinical environments [2][3] - The program will collect standardized data to evaluate clinical performance and patient experience, with initial findings to be presented at the upcoming Alpha Summit [3] Product Information - Obagi's saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology for a stable hyaluronic acid matrix, designed to deliver natural-looking results with high performance [4]

Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practicesIn a release issued under the same headline earlier today by Waldencast plc (NASDAQ: WALD), please note that the quote by Michael Pennington in paragraph 3 was incorrect. The corrected release follows: NEW YORK and DALLAS, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Shenzhen HBN Technology (Group) Company Limited 深圳護家科技 (集 團 )股份有限公司 (a joint stock company incorporated in the Peop ...

LARGO, FL, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical or dermatological advice. This is not a product review, endorsement, or recommendation. Topical skincare products are not substitutes for professional medical evaluation. Always consult a qualified healthcare professional or dermatologist before using any skin treatment product. Affiliate Disclosure: This article contains affiliate links. If you purchase through these link ...

SCOTTSDALE, AZ, Jan. 10, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only and does not constitute medical advice. Skin tags and other growths should be evaluated by a dermatologist before attempting any removal method. Results vary by individual. This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. Enter 2026: Rising Consumer Interest in At-Home Cosmetic Options Consumer search interest in phr ...

As filed with the U.S. Securities and Exchange Commission on December 23, 2025. Registration No. 333-290897 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ AMENDMENT NO. 1 | Cayman Islands | 6770 | 98-1888010 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Classification Code Number) | Identification Number) | 1345 Avenue of the Americas, Fl 47 New York, ...

Core Insights - Waldencast plc (NASDAQ:WALD) is a skincare company known for advanced treatments, established in 1988, with a portfolio including brands like Obagi Medical and Obagi Clinical [1] Financial Performance - The stock target price for Waldencast has been adjusted from $4.13 to $3.25, with D.A. Davidson setting a higher target of $15.50, indicating differing analyst expectations [2][6] - Waldencast reported a net revenue of $65.4 million for Q1 2025, a decline of 4.1% year-over-year, with an adjusted gross margin of 76.4% and adjusted EBITDA of $4.4 million [3][6] - The company is experiencing margin pressure and negative earnings due to high SG&A expenses and significant debt, yet maintains manageable liquidity and a long debt maturity timeline extending to 2030 [5][6] Earnings Call - The Q1 2025 earnings call featured key figures such as CEO Michel Brousset and CFO Manuel Manfredi, with participation from analysts at firms like Alliance Global Partners and TD Cowen [4]

How Actress Lili Reinhart Is Scaling A Skincare Brand And Fixing The Broken Indie Film Model https://t.co/QTAC8jjaQl ...

Actress Lili Reinhart couldn’t find a solution to her acne, so she launched her own skincare line, Personal Day. Thanks to her viral TikTok following, the #ForbesUnder30 alum is now cleaning up with $10 million in sales. Read more: https://t.co/f0BTkfm410 📸: Sebastian Nevols for Forbes ...